Skip to content

nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis

A Prospective Study of a Single Intra-Articular Injection of Autologous Protein Solution in Females With Primary Patellofemoral Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02610192
Enrollment
52
Registered
2015-11-20
Start date
2016-03-31
Completion date
2018-06-30
Last updated
2020-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patellofemoral Osteoarthritis

Keywords

Autologous Protein Solution, Patellofemoral Osteoarthritis, Female

Brief summary

The purpose of this study is to evaluate clinical outcomes following a single injection of nSTRIDE Autologous Protein Solution in females with isolated patellofemoral osteoarthritis. A secondary objective of this study is to document the duration of treatment effect following nSTRIDE injection.

Detailed description

Clinical trials have, in general, formally demonstrated the effectiveness and safety of various autologous therapies for the treatment of knee OA. Differences in the processing of autologous therapies can yield substantial differences in the resulting output. Thus, making generalizations regarding the effectiveness across these autologous therapies is more complicated. Each autologous therapy requires independent efficacy evaluation. nSTRIDE APS has been shown to decrease pain, increase function and have a favorable safety profile in a pilot trial. Further, demonstration of the treatment effects in patellofemoral osteoarthritis, an important subset of knee osteoarthritis is lacking. This study will evaluate a population of female patients with patellofemoral osteoarthritis in which treatment with other modalities provides limited/short lived relief with the hope that APS treatment will provide and extend relief to these patients. The study will document the treatment effects and timeline of treatment effects for nSTRIDE APS following a single injection (per symptomatic knee).

Interventions

DEVICEnSTRIDE Autologous Protein Solution (APS) Kit

Intra-articular injection of APS

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patient must be female * Isolated patellofemoral osteoarthritis (PFOA) in one or both knees as diagnosed by the treating physician * Objective evidence of PFOA on one or both of a radiograph or MRI taken within 3 months of treatment * From 40-65 years of age, inclusive at time of injection * Symptoms return such that there is a need for further treatment within 3 months of a corticosteroid or hyaluronic acid injection * Willing and able to comply with the study procedures * Sign informed consent form

Exclusion criteria

* Any systematic inflammatory condition (e.g. rheumatoid arthritis) * Active malignancy at time of injection * Pregnant at time of injection * Lactating at time of injection * Knee joint infections or skin diseases or infections in the area of the injection site * Leukemia, metastatic malignant cells, or who are receiving chemotherapeutic treatment * Participation in another device, biologic or drug study

Design outcomes

Primary

MeasureTime frameDescription
Pain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems.

Secondary

MeasureTime frameDescription
Function in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems
Function in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems
Quality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems
Pain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale
Symptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems
Function Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale
Patellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe KAKPAQ is a 13-item screening instrument designed to assess patellofemoral pain and instability in adolescents and young adults, with a variable ordinal response format (3-5 choices). The questions included knee functional ability; limping, weight bearing, walking, stairs, squatting, running, jumping, prolonged sitting, pain swelling, painful patellar movement, muscle atrophy and flexion deficiency. Each answer had different scores. To calculate the total score, all items were summarized. The score '0' represented the greatest limitation of knee function, whereas the score '100' indicated the ability to perform most knee functions
Activity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe UCLA Activity Score is a validated measure of subject activity. Subjects rate their current activity level from on a simple scale ranging from 1 to 10. The subject indicated her or his most appropriate activity level, with 1 defined as no physical activity, dependent on others and 10 defined as regular participation in impact sports
Stifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 MonthsBaseline, 1, 3, 6 and 12 MonthsThe NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale

Countries

Belgium

Participant flow

Recruitment details

The study is conducted at a single center in Deurne (Belgium).

Participants by arm

ArmCount
nSTRIDE APS
Intra-articular Injection of Autologous Protein Solution (APS)
50
Total50

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision1
Overall StudyReceived other treatment8

Baseline characteristics

CharacteristicnSTRIDE APS
Age, Customized
Age
50.4 years
STANDARD_DEVIATION 6.5
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Belgium
50 participants
Sex/Gender, Customized
Gender (female)
50 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 50
other
Total, other adverse events
39 / 50
serious
Total, serious adverse events
3 / 50

Outcome results

Primary

Pain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months

The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems.

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSPain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 MonthsBaseline40.3 score on a scaleStandard Deviation 18.7
nSTRIDE APSPain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months1-Month53.5 score on a scaleStandard Deviation 19.8
nSTRIDE APSPain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months3-Months52.5 score on a scaleStandard Deviation 24.1
nSTRIDE APSPain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months6-Months54.9 score on a scaleStandard Deviation 22.6
nSTRIDE APSPain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months12-Months57.3 score on a scaleStandard Deviation 24.8
Secondary

Activity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 Months

The UCLA Activity Score is a validated measure of subject activity. Subjects rate their current activity level from on a simple scale ranging from 1 to 10. The subject indicated her or his most appropriate activity level, with 1 defined as no physical activity, dependent on others and 10 defined as regular participation in impact sports

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSActivity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 MonthsBaseline5.0 score on a scaleStandard Deviation 1.9
nSTRIDE APSActivity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 Months1-Months5.3 score on a scaleStandard Deviation 1.7
nSTRIDE APSActivity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 Months3-Months5.5 score on a scaleStandard Deviation 2
nSTRIDE APSActivity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 Months6-Months5.2 score on a scaleStandard Deviation 1.8
nSTRIDE APSActivity Measured With UCLA Activity Score Questionnaire at 1, 3, 6 and 12 Months12-Months5.6 score on a scaleStandard Deviation 1.9
Secondary

Function in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 Months

The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSFunction in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 MonthsBaseline45.9 score on a scaleStandard Deviation 21.1
nSTRIDE APSFunction in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 Months1-Months58.8 score on a scaleStandard Deviation 21.9
nSTRIDE APSFunction in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 Months3-Months57.9 score on a scaleStandard Deviation 26.8
nSTRIDE APSFunction in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 Months6-Months59.7 score on a scaleStandard Deviation 22.8
nSTRIDE APSFunction in Daily Living (ADL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale ADL at 1, 3, 6 and 12 Months12-Months62.0 score on a scaleStandard Deviation 24.2
Secondary

Function in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 Months

The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSFunction in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 MonthsBaseline11.2 score on a scaleStandard Deviation 13.6
nSTRIDE APSFunction in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 Months1-Months23.0 score on a scaleStandard Deviation 20.1
nSTRIDE APSFunction in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 Months3-Months20.8 score on a scaleStandard Deviation 20.2
nSTRIDE APSFunction in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 Months6-Months22.4 score on a scaleStandard Deviation 23.7
nSTRIDE APSFunction in Sport and Recreation (Sport/Rec) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Sport/Rec at 1, 3, 6 and 12 Months12-Months22.9 score on a scaleStandard Deviation 24.3
Secondary

Function Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 Months

The NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSFunction Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 MonthsBaseline6.6 score on a scaleStandard Deviation 2.1
nSTRIDE APSFunction Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 Months1-Months4.9 score on a scaleStandard Deviation 2.4
nSTRIDE APSFunction Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 Months3-Months4.7 score on a scaleStandard Deviation 2.7
nSTRIDE APSFunction Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 Months6-Months4.7 score on a scaleStandard Deviation 2.7
nSTRIDE APSFunction Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Function at 1, 3, 6 and 12 Months12-Months4.4 score on a scaleStandard Deviation 2.9
Secondary

Pain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months

The NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSPain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 MonthsBaseline6.7 score on a scaleStandard Deviation 2.2
nSTRIDE APSPain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months1-Months4.9 score on a scaleStandard Deviation 2.5
nSTRIDE APSPain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months3-Months5.0 score on a scaleStandard Deviation 2.9
nSTRIDE APSPain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months6-Months4.7 score on a scaleStandard Deviation 2.8
nSTRIDE APSPain Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months12-Months4.5 score on a scaleStandard Deviation 2.9
Secondary

Patellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 Months

The KAKPAQ is a 13-item screening instrument designed to assess patellofemoral pain and instability in adolescents and young adults, with a variable ordinal response format (3-5 choices). The questions included knee functional ability; limping, weight bearing, walking, stairs, squatting, running, jumping, prolonged sitting, pain swelling, painful patellar movement, muscle atrophy and flexion deficiency. Each answer had different scores. To calculate the total score, all items were summarized. The score '0' represented the greatest limitation of knee function, whereas the score '100' indicated the ability to perform most knee functions

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSPatellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 MonthsBaseline48.4 score on a scaleStandard Deviation 13
nSTRIDE APSPatellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 Months1-Months55.4 score on a scaleStandard Deviation 16.3
nSTRIDE APSPatellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 Months3-Months54.8 score on a scaleStandard Deviation 17
nSTRIDE APSPatellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 Months6-Months57.0 score on a scaleStandard Deviation 17
nSTRIDE APSPatellofemoral Pain and Function Measured With Kujala Anterior Knee Pain Assessment Questionnaire (KAKPAQ) Questionnaire at 1, 3, 6 and 12 Months12-Months56.3 score on a scaleStandard Deviation 18.1
Secondary

Quality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 Months

The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSQuality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 MonthsBaseline29.7 score on a scaleStandard Deviation 10.7
nSTRIDE APSQuality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 Months1-Months37.5 score on a scaleStandard Deviation 12.1
nSTRIDE APSQuality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 Months3-Months37.0 score on a scaleStandard Deviation 11.8
nSTRIDE APSQuality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 Months6-Months36.3 score on a scaleStandard Deviation 13.6
nSTRIDE APSQuality of Life (QoL) Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale QoL at 1, 3, 6 and 12 Months12-Months38.2 score on a scaleStandard Deviation 13.5
Secondary

Stifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 Months

The NRS is a validated measure of pain, stiffness and function. The NRS is an 11 point Likert type scale anchored by 0 no pain and 10 worst possible pain. Subjects rate their average pain over the last 24 hours. Likewise subjects rate their stiffness and function on an 11 point Likert type scale

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSStifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 MonthsBaseline6.0 score on a scaleStandard Deviation 2.6
nSTRIDE APSStifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 Months1-Months4.3 score on a scaleStandard Deviation 2.8
nSTRIDE APSStifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 Months3-Months4.5 score on a scaleStandard Deviation 3.1
nSTRIDE APSStifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 Months6-Months4.1 score on a scaleStandard Deviation 2.8
nSTRIDE APSStifness Measured With Numeric Rating Scales (NRS) Questionnaire Subscale Stiffness at 1, 3, 6 and 12 Months12-Months4.0 score on a scaleStandard Deviation 3.1
Secondary

Symptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 Months

The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems

Time frame: Baseline, 1, 3, 6 and 12 Months

Population: Analyses were performed on available data, with no imputation for missing data.

ArmMeasureGroupValue (MEAN)Dispersion
nSTRIDE APSSymptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 MonthsBaseline46.9 score on a scaleStandard Deviation 18.4
nSTRIDE APSSymptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 Months1-Months59.2 score on a scaleStandard Deviation 19.2
nSTRIDE APSSymptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 Months3-Months61.4 score on a scaleStandard Deviation 21.6
nSTRIDE APSSymptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 Months6-Months61.5 score on a scaleStandard Deviation 18.8
nSTRIDE APSSymptoms Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Symptoms at 1, 3, 6 and 12 Months12-Months62.5 score on a scaleStandard Deviation 22.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026